Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/labmed/lmaa049 http://scihub22266oqcxt.onion/10.1093/labmed/lmaa049 32729620!7454767!32729620     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lab+Med 2021 ; 52 (1): 24-35 Nephropedia Template TP {{tp|p=32729620|t=2021. Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside |pdf=|usr=}}{{32729620}} gab.com Text Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside JO: Lab Med http://www.kidney.de/pget.php?&tw=1&pmid=32729620 #FOAvip The COVID-19 pandemic has led to a major setback in both the health and economic sectors across the globe. The scale of the problem is enormous because we still do not have any specific anti-SARS-CoV-2 antiviral agent or vaccine. The human immune system has never been exposed to this novel virus, so the viral interactions with the human immune system are completely naive. New approaches are being studied at various levels, including animal in vitro models and human-based studies, to contain the COVID-19 pandemic as soon as possible. Many drugs are being tested for repurposing, but so far only remdesivir has shown some positive benefits based on preliminary reports, but these results also need further confirmation via ongoing trials. Otherwise, no other agents have shown an impactful response against COVID-19. Recently, research exploring the therapeutic application of mesenchymal stem cells (MSCs) in critically ill patients suffering from COVID-19 has gained momentum. The patients belonging to this subset are most likely beyond the point where they could benefit from an antiviral therapy because most of their illness at this stage of disease is driven by inflammatory (over)response of the immune system. In this review, we discuss the potential of MSCs as a therapeutic option for patients with COVID-19, based on the encouraging results from the preliminary data showing improved outcomes in the progression of COVID-19 disease. Twit Text FOAVip Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside ????Lab Med http://www.kidney.de/pget.php?&tw=1&pmid=32729620 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32729620 #FOAvip English Wikipedia <ref>{{Cite pmid|32729620}}</ref> Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside #MMPMID32729620 Sahu KK; Siddiqui AD; Cerny J Lab Med 2021[Jan]; 52 (1): 24-35 PMID32729620show ga The COVID-19 pandemic has led to a major setback in both the health and economic sectors across the globe. The scale of the problem is enormous because we still do not have any specific anti-SARS-CoV-2 antiviral agent or vaccine. The human immune system has never been exposed to this novel virus, so the viral interactions with the human immune system are completely naive. New approaches are being studied at various levels, including animal in vitro models and human-based studies, to contain the COVID-19 pandemic as soon as possible. Many drugs are being tested for repurposing, but so far only remdesivir has shown some positive benefits based on preliminary reports, but these results also need further confirmation via ongoing trials. Otherwise, no other agents have shown an impactful response against COVID-19. Recently, research exploring the therapeutic application of mesenchymal stem cells (MSCs) in critically ill patients suffering from COVID-19 has gained momentum. The patients belonging to this subset are most likely beyond the point where they could benefit from an antiviral therapy because most of their illness at this stage of disease is driven by inflammatory (over)response of the immune system. In this review, we discuss the potential of MSCs as a therapeutic option for patients with COVID-19, based on the encouraging results from the preliminary data showing improved outcomes in the progression of COVID-19 disease. |CD4-Positive T-Lymphocytes/immunology/virology[MESH] |CD8-Positive T-Lymphocytes/immunology/virology[MESH] |COVID-19/diagnosis/mortality/*pathology/*therapy[MESH] |Critical Illness[MESH] |Cytokine Release Syndrome/immunology/mortality/*prevention & control/virology[MESH] |Cytokines/antagonists & inhibitors/genetics/immunology[MESH] |Dendritic Cells/immunology/virology[MESH] |Disease Progression[MESH] |Humans[MESH] |Mesenchymal Stem Cell Transplantation/*methods[MESH] |Mesenchymal Stem Cells/cytology/immunology[MESH] |SARS-CoV-2/*pathogenicity[MESH] |Severity of Illness Index[MESH] |Survival Analysis[MESH]Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside (epmc).pdf DeepDyve Pubget Overpricing